Pan-genotypic regimens for chronic infection with genotypes 1–6 HCV

There are now three pan-genotypic DAA regimens listed on the PBS: sofosbuvir plus velpatasvir, glecaprevir plus pibrentasvir, and sofosbuvir plus velpatasvir plus voxilaprevir. The first-line regimens for treatment-naive people living with hepatitis C are sofosbuvir plus velpatasvir or glecaprevir plus pibrentasvir. The recommended treatment regimen for people who do not respond to sofosbuvir plus velpatasvir or glecaprevir plus pibrentasvir is the triple-combination regimen of sofosbuvir plus velpatasvir plus voxilaprevir (Table 2).